Axela, PAML Collaborate on Immune Status Multiplex Assays | GenomeWeb

NEW YORK (GenomeWeb) – Pathology Associates Medical Laboratories (PAML) today announced that it has entered into a collaboration with Axela to develop multiplex assays to detect patient immunity to diseases that can be prevented with vaccines.

The serologic assays will measure antibodies to a wide range of viruses including measles, mumps, and rubella to help determine a patient's immunity to those diseases. The terms of the agreement also call for multiplex targets beyond the initial serological assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.